|
Media Releases |
Financial Reports |
Presen-tations |
|
11/30/2004
|
|
|
|
| Lonza Launches Natrulon® DermaSphere Oleosome Technology for the Personal Care Industry |
| New self-emulsifying technology provides formulators with unique attributes, saves time and manufacturing costs |
Lonza has announced the launch of the all-natural, multifunctional Natrulon® DermaSphere™ Oleosome technology. The new technology performs as an emollient, emulsifier and moisturizer all in one product. This mild and non-sensitizing novel product can comprise the entire oil phase of a cosmetic emulsion as well as reduce manufacturing costs and ease formulation through cold processing techniques.
The DermaSphere™ Oleosome technology is based on a natural oil-in-water emulsion derived from plant oilseeds. The emulsion is comprised of naturally occurring oil droplets called Oleosomes, in which the oil is surrounded by a shell of phospholipid and a unique protein called oleosin. The Oleosome emulsion is cosmetically elegant, extremely flexible, and offers multiple functions as an emulsifier, emollient, and carrier/delivery system for small molecule actives.
The DermaSphere™ Oleosome technology was developed by SemBioSys Genetics Inc., a Canadian biotechnology company, and has broad patent protection in the U.S., Canada and elsewhere. Lonza and SemBioSys joined forces in May of 2004 with the execution of a licensing agreement for exclusive global rights to the technology for use in Personal Care applications. Lonza and SemBioSys have worked closely together to bring this novel, plant-derived ingredient system quickly to the Personal Care market. Natrulon® OSF - Oleosomes derived from safflower seeds - is the first product launched in this platform of unique, all-natural ingredients.
"The DermaSphere™ Oleosome technology is a breakthrough in cosmetic formulating," comments Carl Cappabianca, Vice President Global Marketing & Technology for Lonza's Health, Hygiene and Personal Care team. "The unique attributes of Oleosomes allow this technology to be used in a wide range of applications, saving formulators and plant personnel time and effort while lowering manufacturing costs."
From a formulating perspective, the DermaSphere™ Oleosome technology can be used in moisturizing creams, sunscreens, ointments, lotions, eye-care products and many other products. The self-emulsifying Oleosomes can replace the entire oil phase of the cosmetic emulsion, including traditional emulsifiers and surfactants and simplify the cosmetic formulation process. From a manufacturing perspective, the DermaSphere™ Oleosome technology allows for cold processing which can increase production throughput, lower labor requirements and reduce energy costs.
"The launch of the Natrulon® DermaSphere™ Oleosome technology by our partner Lonza is an important milestone for SemBioSys" said Andrew Baum, President and CEO of SemBioSys Genetics Inc. "The DermaSphere™ launch validates the commercial utility of our technology platform and reflects SemBioSys' ability to bring products to market through successful partnerships".
The Natrulon® DermaSphere™ Oleosome technology represents an on-going commitment by Lonza to provide the cosmetic market both cutting-edge technology and world-class technical support.
About SemBioSys Genetics Inc. (www.sembiosys.com)
SemBioSys Genetics Inc. is a privately held biotechnology company focused on the development, commercialization and production of protein-based pharmaceuticals and non-pharmaceutical products based on our plant genetic engineering skills and our proprietary oilbody-oleosin technology platform-the Stratosome™ Biologics System. In the past 12 months, SemBioSys has executed five funded partnership agreements with Syngenta Participations AG, Martek Biosciences Corporation, Lonza, Inc., Dow AgroSciences LLC and Arcadia BioSciences, Inc.
About Lonza (www.lonza.com)
Lonza is a life sciences driven company, headquartered in Switzerland, which generated sales of CHF 2.24 billion in 2003. It operates 18 production and R&D facilities in eight countries and employs 5660 people worldwide. Lonza is one of the leading custom manufacturers of chemical intermediates and active ingredients as well as biopharmaceuticals for the pharmaceutical and agrochemical industries. In addition, Lonza also offers organic intermediates for a wide range of applications and provides antimicrobial and associated products as well as polymer intermediates and compounds.
In the Personal Care industry, Lonza is one of the world's leading specialty chemical companies with substantial global resources in research and development, technical and applications service and broadly based manufacturing capability. Lonza has an on-going commitment to developing technology and solutions to the Personal Care industry in a variety of areas including world-leading positions in preservatives and specialty active compounds.
Natrulon is a registered trademark of Lonza Inc. DermaSphere and Stratosome are trademarks of SemBioSys Genetics Inc.
For further information please contact:
Christine Casper
Communications Manager
Lonza Inc
Tel +1 201 316 9236
Fax +1 201 785 9013
christine.casper@lonza.com
Carl Cappabianca
Vice President Marketing & Technology
Lonza Inc
Tel +1 201 316 9305
Fax +1 201 696 3458
carl.cappabianca@lonza.com
Mr Ross Marshall
SemBioSys Genetics Inc
The Equicom Group
Tel +1 416 815 0700 ext. 238
Fax +1 416 815 0080
rmarshall@equicomgroup.com
Mr Andrew Baum
President and Chief Executive Officer
Tel +1 403 250 5424 ext. 24
Fax +1 403 250 3886
bauma@sembiosys.com
Internet: www.sembiosys.com |
|
|
